Skip to content
OpenCapital
Get started

AngioDynamics ANGO EPS (Diluted)

EPS (Diluted) at other companies

Abbott logo
AbbottABT
$0.61-19.7%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
-$1.11-204%
TFX
TeleflexTFX
-$0.18-109%
Stryker logo
StrykerSYK
$1.93+14.2%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$0.68+38.8%
ICU Medical logo
ICU MedicalICUI
$1.20+290%

Other financials

Income statement

See full
Revenue$78.4M+8.9%
Gross profit$41.5M+6.7%
Operating income-$13.0M-29.8%
Net income-$8.1M-83.4%

Balance sheet

See full
Cash & equivalents$37.8M-15.5%
Total debt$7.9M+10.2%
Total equity$173.4M-6.7%
Total assets$260.7M-8.7%

Cash flow

See full
Operating cash flow-$3.1M+76.4%
CapEx$1.0M-43.5%
Free cash flow-$4.1M+72.4%

Valuation

See full
Market cap$564.42M+38.7%
Enterprise value$534.51M+48.0%
P/S1.8×+0.4×

Profitability

See full
Gross margin54.3%-0.1pp
Operating margin-11.3%-2.9pp
Net margin-10%-2.4pp
FCF margin5.5%—

Returns & leverage

See full
Return on equity-17.5%-2.2pp
Debt / equity0×0.0×
Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AngioDynamics's EPS (diluted)?
AngioDynamics (ANGO) reported EPS (diluted) of -$0.19 in Q4 2025.
How has AngioDynamics's EPS (diluted) changed year-over-year?
AngioDynamics's EPS (diluted) decreased by 72.7% year-over-year, from -$0.11 to -$0.19.
What is the long-term trend for AngioDynamics's EPS (diluted)?
Over 4 years (2021 to 2025), AngioDynamics's EPS (diluted) has grown at a 0.6% compound annual growth rate (CAGR), from -$0.81 to -$0.83.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.